Basic Information
| LncRNA/CircRNA Name | LINC01278 |
| Synonyms | NA |
| Region | GRCh38_X:63343227-63561071 |
| Ensemble | ENSG00000235437 |
| Refseq | NR_015353 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot, Microarray, RIP |
| Sample | osteosarcoma tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | LINC01278 was a competing endogenous RNA of parathyroid hormone type 1 receptor (PTHR1) in osteosarcoma by sponging miR-133a-3p, which was considered as a tumor inhibitor in osteosarcoma. |
| Pubmed ID | 31994731 |
| Year | 2020 |
| Title | Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling |
External Links
| Links for LINC01278 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |